Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%
Akebia Therapeutics, Inc. (AKBA - Free Report) was a big mover last session, as the company saw its shares rise almost 6% on the day. The move came after the company signed an expanded agreement with Otsuka Pharmaceutical on its anemia drug. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 44% in the past one-month time frame.
The company has seen no positive or negative estimate revision in the past 30 days. Also, its Zacks Consensus Estimate remained unchanged over the same timeframe. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Akebia Therapeutics currently carries a Zacks Rank #3 (Hold).
Akebia Therapeutics, Inc. Price
Akebia Therapeutics, Inc. Price | Akebia Therapeutics, Inc. Quote
A top-ranked stock in the Medical – Drugs industry is Grifols, S.A. (GRFS - Free Report) sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is AKBA going up? Or down? Predict to see what others think: Up or Down
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500. See today's Zacks "Strong Sells" absolutely free >>.